Ravidasvir

From Infogalactic: the planetary knowledge core
Jump to: navigation, search

Ravidasvir (PPI-668) is an NS5A inhibitor in clinical trials for chronic hepatitis C Genotype-4.[1]

Clinical trial results were announced in Nov 2015.[2]

References

<templatestyles src="Reflist/styles.css" />

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
  1. ↑ A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4
  2. ↑ Good Results for Sovaldi and Ravidasvir Treating Hepatitis C Genotype 4
Retrieved from "https://infogalactic.com/w/index.php?title=Ravidasvir&oldid=720019856"